Knight Therapeutics Inc. (TSX:GUD)

Market Cap	1.01B +62.8%
Revenue (ttm)	547.31M +42.3%
Net Income	14.87M +3,782.8%
EPS	0.15 +8,835.1%
Shares Out	98.23M
PE Ratio	68.59
Forward PE	93.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,715
Open	10.29
Previous Close	10.29
Day's Range	10.01 - 10.29
52-Week Range	5.66 - 10.37
Beta	0.04
Analysts	Strong Buy
Price Target	11.19 (+10.9%)
Est. Earnings	Nov 12, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 830
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD

Analyst Summary

According to 7 analysts, the average rating for GUD stock is "Strong Buy." The 12-month stock price target is $11.19, which is an increase of 10.90% from the latest price.

Price Target

$11.19

(10.90% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 23, 2026

Data Sources Report a data error